MIR152, microRNA 152, 406943

N. diseases: 136; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.380 AlteredExpression disease BEFREE WITHDRAWN: Downregulation of MicroRNA-152 and Inhibition of Cell Proliferation, Migration, and Invasion in Breast Cancer. 28653610 2017
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.380 AlteredExpression disease BEFREE WITHDRAWN: Downregulation of MicroRNA-152 and Inhibition of Cell Proliferation, Migration, and Invasion in Breast Cancer. 28653610 2017
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.100 AlteredExpression phenotype BEFREE WITHDRAWN: Downregulation of MicroRNA-152 and Inhibition of Cell Proliferation, Migration, and Invasion in Breast Cancer. 28653610 2017
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.100 Biomarker phenotype BEFREE When miR-152 was enhanced, the invasion and migration of NPC cells were inhibited. 29628766 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE We validated 12 miRNAs implicated in tumor development using primary STS samples and selected miR-152 for further analysis in STS-derived cell lines. 27900663 2017
CUI: C0011854
Disease: Diabetes Mellitus, Insulin-Dependent
Diabetes Mellitus, Insulin-Dependent 		0.010 AlteredExpression disease BEFREE We observed strong evidence for the association of hsa-miR-152-3p plasma levels and DN in patients with T2D, confirming an association previously observed in patients with type 1 diabetes. 29361146 2018
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.030 AlteredExpression disease BEFREE We observed strong evidence for the association of hsa-miR-152-3p plasma levels and DN in patients with T2D, confirming an association previously observed in patients with type 1 diabetes. 29361146 2018
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy 		0.010 GeneticVariation disease BEFREE We observed strong evidence for the association of hsa-miR-152-3p plasma levels and DN in patients with T2D, confirming an association previously observed in patients with type 1 diabetes. 29361146 2018
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.060 PosttranslationalModification phenotype BEFREE We identified E2F3, MET, and Rictor as novel candidate targets of miR-152, suggesting how its epigenetic silencing can drive endometrial carcinogenesis. 21868754 2011
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.040 Biomarker disease BEFREE We further characterized the hypermethylation-dependent inhibition of miR-152, -10b-5p and -34c-3p which was shown to exert a putative tumor suppressive role in MM. 25330074 2014
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.040 AlteredExpression disease BEFREE We found that target genes of the most differentially expressed miRNAs are directly involved in the pathogenesis of MM; specifically, the inhibition of hsa-miR-425, hsa-miR-152 and hsa-miR-24, which are all downregulated in h-MM, leads to the overexpression of CCND1, TACC3, MAFB, FGFR3 and MYC, which are the also the oncogenes upregulated by the most frequent IgH chromosomal translocations occurring in nh-MM. 23174883 2013
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.040 AlteredExpression disease BEFREE We found that levels of H19 and BRD4 were up-regulated, and the expression of miR-152-3p was down-regulated in MM patients. 31712391 2020
CUI: C1512409
Disease: Hepatocarcinogenesis
Hepatocarcinogenesis 		0.040 Biomarker disease BEFREE We found that dysregulation of MIR7 contributes to the initiation and progression of inflammation-induced gastric cancer; dysregulation of MIR9 contributes to HIV-1 infection to hijack CD4+ T cells through dysfunction of the immune and hormone pathways; dysregulation of MIR139-5p, MIRLET7i, and MIR10a contributes to the HIV-1 integration/replication stage; dysregulation of MIR101, MIR141, and MIR152 contributes to the HIV-1 virus assembly and budding mechanisms; dysregulation of MIR302a contributes to not only microvesicle-mediated transfer of miRNAs but also dysfunction of NF-κB signaling pathway in hepatocarcinogenesis. 26897165 2016
CUI: C0021051
Disease: Immunologic Deficiency Syndromes
Immunologic Deficiency Syndromes 		0.010 Biomarker group BEFREE We found that dysregulation of MIR7 contributes to the initiation and progression of inflammation-induced gastric cancer; dysregulation of MIR9 contributes to HIV-1 infection to hijack CD4+ T cells through dysfunction of the immune and hormone pathways; dysregulation of MIR139-5p, MIRLET7i, and MIR10a contributes to the HIV-1 integration/replication stage; dysregulation of MIR101, MIR141, and MIR152 contributes to the HIV-1 virus assembly and budding mechanisms; dysregulation of MIR302a contributes to not only microvesicle-mediated transfer of miRNAs but also dysfunction of NF-κB signaling pathway in hepatocarcinogenesis. 26897165 2016
CUI: C2363741
Disease: HIV-1 infection
HIV-1 infection 		0.010 Biomarker disease BEFREE We found that dysregulation of MIR7 contributes to the initiation and progression of inflammation-induced gastric cancer; dysregulation of MIR9 contributes to HIV-1 infection to hijack CD4+ T cells through dysfunction of the immune and hormone pathways; dysregulation of MIR139-5p, MIRLET7i, and MIR10a contributes to the HIV-1 integration/replication stage; dysregulation of MIR101, MIR141, and MIR152 contributes to the HIV-1 virus assembly and budding mechanisms; dysregulation of MIR302a contributes to not only microvesicle-mediated transfer of miRNAs but also dysfunction of NF-κB signaling pathway in hepatocarcinogenesis. 26897165 2016
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.060 AlteredExpression disease BEFREE We found that miR-152-3p was underexpressed in PCa and that lower expression levels were associated with promoter hypermethylation in accordance with TCGA dataset analysis. 29599847 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.060 AlteredExpression disease BEFREE We found that miR-152-3p was underexpressed in PCa and that lower expression levels were associated with promoter hypermethylation in accordance with TCGA dataset analysis. 29599847 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.090 AlteredExpression disease BEFREE We found higher signals for miR-122 and miR-152 in non-tumor liver and HCC tissues compared to control tissues. 28512857 2018
CUI: C0025202
Disease: melanoma
melanoma 		0.010 Biomarker disease BEFREE We determined that HOTAIR acts as a ceRNA to promote malignant melanoma progression by sponging miR-152-3p. 29156728 2017
CUI: C0029463
Disease: Osteosarcoma
Osteosarcoma 		0.040 Biomarker disease BEFREE We demonstrated that microRNA‑152 inhibits cell proliferation of osteosarcoma through DKK1 by directly targeting Wnt/β‑catenin signaling pathway. 29845282 2018
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone 		0.040 Biomarker disease BEFREE We demonstrated that microRNA‑152 inhibits cell proliferation of osteosarcoma through DKK1 by directly targeting Wnt/β‑catenin signaling pathway. 29845282 2018
CUI: C1332986
Disease: Childhood Osteosarcoma
Childhood Osteosarcoma 		0.040 Biomarker disease BEFREE We demonstrated that microRNA‑152 inhibits cell proliferation of osteosarcoma through DKK1 by directly targeting Wnt/β‑catenin signaling pathway. 29845282 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.060 Biomarker phenotype BEFREE We also investigated and confirmed the role of miR-152-5p in GC by a series of experiments, and found that miR-152-5p modulated cell viability, migration, invasion, and cell-cycle progression of human GC cells, and also inhibited tumor growth and metastasis <i>in vivo</i> partially by targeting PIK3CA. 29904279 2018
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.080 Biomarker disease BEFREE We also investigated and confirmed the role of miR-152-5p in GC by a series of experiments, and found that miR-152-5p modulated cell viability, migration, invasion, and cell-cycle progression of human GC cells, and also inhibited tumor growth and metastasis <i>in vivo</i> partially by targeting PIK3CA. 29904279 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.080 Biomarker disease BEFREE We also investigated and confirmed the role of miR-152-5p in GC by a series of experiments, and found that miR-152-5p modulated cell viability, migration, invasion, and cell-cycle progression of human GC cells, and also inhibited tumor growth and metastasis <i>in vivo</i> partially by targeting PIK3CA. 29904279 2018